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Abstract
Background: A high incidence of rash has been reported in HIV-1 patients who received the anti-
retroviral drug nevirapine. In addition, several studies have suggested that polymorphisms of human
leukocyte antigen (HLA) genes may play important roles in nevirapine-induced rash. The aim of the
present study was to evaluate the effects of different HLA-C  alleles on rash associated with
nevirapine in patients who started highly active anti-retroviral therapy (HAART) containing
nevirapine in Thailand.
Results:  A case-control study was carried out involving HIV-1 patients under treatment at
Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand between March 2007 and
March 2008. The study included all HIV/AIDS patients being treated with nevirapine-containing
regimens. The study population comprised 287 HIV/AIDS patients of whom 248 were nevirapine-
tolerant and 39 developed rash after nevirapine treatment. From the nevirapine-tolerant patients,
60 were selected as the control group on the basis of age, sex, and therapy history matched for
nevirapine-induced rash cases. We observed significantly more HLA-Cw*04 alleles in nevirapine-
induced rash cases than in nevirapine-tolerant group, with frequencies of 20.51% and 7.50%,
respectively (P = 0.009). There were no significant differences between the rash and tolerant
groups for other HLA-C alleles except for HLA-Cw*03 (P = 0.015).
Conclusion: This study suggests that HLA-Cw*04 is associated with rash in nevirapine treated
Thais. Future screening of patients' HLA may reduce the number of nevirapine-induced rash cases,
and patients with alleles associated with nevirapine-induced rash should be started on anti-
retroviral therapy without nevirapine.
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Background
Highly active antiretroviral therapy (HAART) has signifi-
cantly improved the prognosis of HIV-1-infected patients
and prolonged AIDS-free survival[1]. HAART has also
resulted in immune restoration and reduction of morbid-
ity and mortality even for patients with advanced HIV-1
infection[1,2]. Nevirapine (NVP) is a non-nucleoside
reverse transcriptase inhibitor (NNRTI) that has been
shown to have high antiretroviral efficacy [3]. NVP-based
HAART regimens have therefore been widely used in
resource-limited countries because of their efficacy, avail-
ability and relatively low cost. In Thailand, the Govern-
ment Pharmaceutical Organization (GPO) has produced
GPOvir, a low cost (US$ 30 per month) and fixed-dose
combination of NVP, stavudine (D4T), and lamivudine
(3TC), which has been commercially available since
March 2002.
However, NVP-associated rash has been reported to be as
high as 48% after the start of treatment with this inhibitor
[4]. Nearly 90% of the side effects of GPOvir are thought
to be due to NVP hypersensitivity [5]. Skin rash is the
most common adverse drug reaction associated with NVP,
and hypersensitivity reaction to NVP is rapid and severe
when drug administration is suspended and re-challenged
[6]. Most patients develop rash between the first and third
week of treatment [7], including the more severe forms of
rash such as extensive maculopapular rash, serum sick-
ness-like reaction, hypersensitivity syndrome, Steven-
Johnson syndrome and toxic epidermal necrosis [7,8].
NVP-induced rash has been reported in 4.3-36% of adults
[9,10] with the incidence for Thai patients ranging from 6
to 21% [5], reflecting the comparatively high incidence of
rash in Asians [11]. Several features of NVP hypersensitiv-
ity suggest that genetic factors may play an important pre-
disposing role in NVP hypersensitivity, in which NVP
itself or NVP-induced antigens may trigger an immuno-
logical response that is dependent on CD4 T lymphocytes
in susceptible hosts. This supports the hypothesis that the
hypersensitivity reaction to NVP may be HLA-associated
[9,12,13], while HLA-alleles have also been identified as
clinically relevant susceptibility markers for hypersensitiv-
ity reaction to another antiretroviral drug [14]. Recent
studies have shown that in Japan the HLA-Cw*08 allele is
associated with NVP hypersensitivity [15]. The objective
of the study presented here was to compare allele fre-
quency of HLA-C in Thai patients with rash who had to
change from GPOvir to a regime containing efavirenz and
those who were NVP-tolerant.
Results
A case-control study was carried out. The study popula-
tion comprised 287 HIV/AIDS patients of whom 248 were
nevirapine-tolerant and 39 developed rash. From the nev-
irapine-tolerant patients, 60 were selected as the control
group on the basis of age, sex, and therapy history
matched for nevirapine-induced rash cases. As shown in
Table 1, the demographic and clinical characteristics of
patients with NVP-induced rash were very similar to those
of NVP-tolerant patients. The medians of CD4 cell counts
of NVP-induced rash and NVP-tolerant group were com-
parable at both time points of immediately before NVP
treatment and 6 month after treatment. It is known that
HIV-infected patients frequently suffered from allergic
drug reactions [16]. Nearly all of rash cases (37 out of 39)
used steroids and more than half (35 out of 60 cases) of
NVP-tolerant patients also used steroids. Four out of 35
NVP-tolerant steroid users had developed mild rash that
could be controlled by steroid. Remaining 31 NVP-toler-
ant patients used steroid to suppress allergic reactions
including chronic allergic skin, rhinitis, asthma, and drug
reactions upon Pneumocystis carinii pneumonia treat-
Table 1: Demographics and immunological variables of the NVP-induced rash and NVP-tolerant groups
Variables NVP-induced rash NVP-tolerant P value
(n = 39) (n = 60)
Age (median IQR) 39.0 (34.0-44.0) 38.0 (35.0-41.75) *0.71
Sex [n(%)] **0.68
Male 22 (56.41%) 31 (51.67%)
Female 17 (43.59%) 29 (48.33%)
Duration of Treatment, year (median IQR) 1 (0-3) 1 (0-2.75) *0.47
Pre-NVP-treatment CD4 T-cell count × 106/l 43.5 55 *0.71
(median IQR) (19.50-135.50) (28.25-137.50)
Post-NVP-treatment CD4 T-cell count × 106/l 243 241 *0.98
(median IQR) (155.00-328.00) (185.00-312.25)
*Mann-Whitney U-test
**Chi square testAIDS Research and Therapy 2009, 6:22 http://www.aidsrestherapy.com/content/6/1/22
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ment, and immune reconstitution inflammatory syn-
drome. The NVP-induced rash cases manifested severe
rash, which could not be suppressed by steroid, and had
to change the regimen.
The frequencies of the HLA-C alleles identified in the 39
samples in the NVP-induced rash group and 60 samples
in the NVP tolerant group are presented in Table 2. Fre-
quency of HLA-Cw*04 was approximately 21% for the
patients with NVP-induced rash and 7.5% for the NVP-
tolerant group, showing a statistically significant differ-
ence in HLA-Cw*04 allele frequency (P = 0.0088, Fisher's
exact test). The reported HLA-Cw*04 allele frequency for
the normal Thai population (0.102) [17] is higher than
that of the NVP-tolerant group (0.075) and lower than
that of the NVP-induced rash group (0.205). Although
statistical significance of this difference was lost after strin-
gent Bonferroni correction (Pc = 0.088), these results sug-
gested that HLA-Cw*04 was associated with NVP-induced
rash in HIV-1 infected Thai patients. One-third of the
patients with NVP-induced rash (13 out of 39) carried
HLA-Cw*04 in comparison with 15% of the NVP-tolerant
patients (9 out of 60) (P = 0.047, Fisher's exact test; Pc =
0.47). When we compared 39 NVP-induced rash patients
with 25 NVP-tolerant patients who did not receive steroid,
the concentration of HLA-Cw*04 allele in NVP rash cases
was still apparent (0.205 vs 0.060, P = 0.04, Fisher's exact
test).
In contrast to HLA-Cw*04, fewer HLA-Cw*03 alleles were
found in patients with NVP-induced rash than in NVP-tol-
erant ones (0.051 and 0.167) (P = 0.015, Fisher's exact
test; Pc = 0.15). Approximately 7.7% of patients with
NVP-induced rash (3 out of 39) carried HLA-Cw*03 in
comparison with 30% of the NVP-tolerant patients (18
out of 60) (P = 0.011 Fisher's exact test, Pc = 0.11). There
were no significant differences between the NVP-induced
rash and NVP-tolerant groups in allele frequencies of
HLA-Cw*01, HLA-Cw*05, HLA-Cw*06, HLA-Cw*07,
HLA-Cw*08, HLA-Cw*12, HLA-Cw*14, and HLA-Cw*15.
Other HLA-Cw* alleles were not detected in the tested
samples. The NVP-tolerant group allele frequencies of
HLA-Cw*03  (0.167),  HLA-Cw*08  (0.125) and HLA-
Cw*12 (0.067) were very similar to those of the normal
Thai population (0.174, 0.144 and 0.06, respectively)
[17], which suggests that our genotyping was accurate.
HLA-DRB1*01 was reported to be associated with NVP
hypersensitivity in Australian [13] and French [18]
cohorts. We therefore performed PCR-sequence specific
oligonucleotide probe (SSOP) method to detect HLA-
DRB1*01 alleles. Contrary to our expectation, we failed to
detect HLA-DRB1*01 allele in 39 NVP-induced rash cases,
while we detected five of this allele in 60 NVP-tolerant
patients. This result suggested that the HLA-DRB1*01
allele may not involved in NVP rash in Thai population.
The C allele of the SNP rs9264942, located in the
5'upstream region of the HLA-C gene, was reported to
associate with higher levels of HLA-C expression and
HLA-Cw*04 allele [19]. To know whether or not higher
levels of HLA-C  gene expression associated with NVP-
induced rash, we genotyped rs9264942 SNP by TaqMan
SNP genotyping system. The C allele frequency in 39 NVP
rash cases was 0.45, while it was 0.38 in 60 NVP-tolerant
patients (P = 0.36, Chi square test). This result suggested
that the HLA-Cw*04 allele itself rather than the relative
high levels of HLA-C expression was involved in NVP-
induced rash.
Discussion
In the study reported here, we genotyped HLA-C alleles of
39 patients with NVP-induced rash and 60 NVP-tolerant
Thai patients, and found that frequency of HLA-Cw*04
was higher in NVP-induced rash Thai patients than in
NVP-tolerant patients. While the number of samples in
Table 2: Occurrence of HLA-C alleles in the nevirapine (NVP)-rash cases and NVP-tolerant controls in Thailand
Allele NVP-induced rash number (%) NVP-tolerant number (%) *P value
HLA-Cw*01 12 (15.38) 12 (10.00) NS
HLA-Cw*03 4 (5.13) 20 (16.67) 0.01
HLA-Cw*04 16 (20.51) 9 (7.50) 0.009
HLA-Cw*05 2 (2.56) 3 (2.50) NS
HLA-Cw*06 8 (10.26) 9 (7.50) NS
HLA-Cw*07 19 (24.36) 39 (35.50) NS
HLA-Cw*08 9 (11.54) 15 (12.50) NS
HLA-Cw*12 6 (7.69) 8 (6.67) NS
HLA-Cw*14 03  ( 2 . 5 0 ) N S
HLA-Cw*15 2 (2.56) 2 (1.67) NS
Total 78 120
*Fisher's exact test
NS: P > 0.05AIDS Research and Therapy 2009, 6:22 http://www.aidsrestherapy.com/content/6/1/22
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our study is small, the increased frequency of HLA-Cw*04
in patients with NVP-induced rash suggested that this
allele plays an important role in the development of rash
after GPOvir treatment. HLA-Cw*04 was found to be asso-
ciated with rapid development of AIDS-defining condi-
tions in Caucasians [20,21] but to have a protective effect
in African Americans [22]. In hepatitis C virus infection
cases, HLA-Cw*04 was associated with viral persistence
[23].
Previous studies [15,24] have suggested that HLA-Cw*08
is associated with NVP hypersensitivity. Littera et al. stud-
ied 49 Sardinian HIV-1-positive patients treated with NVP
and reported that HLA-Cw*08 and/or HLA-B*14(65) is
associated with NVP hypersensitivity [24]. Subsequently,
Gatanaga et al. studied HIV-1 infected individuals in Japan
[15]. In this study, 41 patients had a history of NVP treat-
ment, 12 of whom showed NVP hypersensitivity. The fre-
quency of HLA-B*14 is nearly 0% in Japan. On the other
hand, the frequency of HLA-Cw*08-positive patients in
the NVP hypersensitive group was 42%, which was signif-
icantly higher than that the NVP tolerant group (10%)
[15]. In our study, however, the frequencies of HLA-
Cw*08 in the NVP rash and tolerant groups were 0.115
and 0.125, respectively, without any significant difference
between the two groups (P = 1.000, Fisher's test).
Although the precise reason for the difference between the
findings of these previous studies and ours is not clear at
present, there were several differences between them.
First, we genotyped approximately three times more
patients with NVP-induced rash than was done in the pre-
vious studies. Second, our study focused on rash after NVP
treatment but the other studies dealt with patients with
rash and/or hepatotoxicity. Furthermore, it is possible
that the levels of linkage disequilibrium between HLA-C
alleles and those of other HLA locus and/or other genes
differ among different ethnic groups. As described above,
HLA-Cw*04 was associated with rapid AIDS progression
in Caucasians [20,21] but to have a protective effect in
African Americans [22]. Thus, it is possible that other
SNP(s) or HLA allele(s) responsible for NVP-induced rash
is in a stronger linkage disequilibrium with HLA-Cw*04 in
Thais than the other ethnic groups tested previously.
Previous studies have also suggested that higher CD4
counts at baseline increased risk of NVP-induced rash [25-
30]. In our study, however, the median baseline CD4
counts of NVP-induced rash cases (43.5 cells/μl) was very
similar to that of 248 NVP-tolerant patients (43 cells/μl).
The effects of high baseline CD4 counts on risk of NVP-
induced rash were reportedly observed mainly in patients
whose CD4 counts were over 250 cells/μl [29]. Accord-
ingly, nearly all of patients in our study started NVP-con-
taining regimen after their CD4 counts dropped below
250 cells/μl. Therefore, it is also possible that low baseline
CD4 counts in our study limit the ability to detect an HLA
association reported previously [15,24]. Nevertheless, our
results are practically meaningful since most of HIV-1-
infected individuals in Thailand start antiretroviral treat-
ment after their CD4 counts drop below 250 cells/μl.
One report from Thailand demonstrated that the effects of
high baseline CD4 counts on risk of NVP-induced rash
were still observed even in patients whose baseline CD4
counts were below 250 cells/μl, although the levels of
such effects was very small in patients whose baseline
CD4 counts were below 200 cells/μl [30]. Therefore, we
divided patients according to their baseline CD4 counts.
When we picked up patients whose baseline CD4 counts
were over 100 cells/μl, HLA-Cw*04 allele frequency was
0.25 in 14 NVP-induced rash cases and 0.025 in 20 NVP-
tolerant patients. Statistical significance of this difference
rather increased in these groups (P = 0.0068). When we
picked up patients whose baseline CD4 were less than 100
cells/μl, HLA-Cw*04 allele frequency was 0.2045 in 22
NVP-induced rash cases and 0.0897 in 39 NVP-tolerant
patients. Although there was an apparent trend towards
high HLA-Cw*04 frequency in NVP-induced rash cases,
statistical significance of the difference greatly reduced in
these groups (P = 0.094). Therefore, the difference in the
allele frequency was more prominent in patients with
higher CD4 counts even in our patient group.
During the preparation of this manuscript, Chantarangsu
et al. reported a strong association between HLA-B*3505
and NVP-induced skins rash in HIV-infected Thai patients
[31]. Our results at least partly confirm theirs since HLA-
Cw*0401 showed the second highest levels of difference
in allele frequency between NVP-rash and NVP-tolerant
patients in their study [31]. It is known that HLA-Cw*04
is in a linkage disequilibrium with HLA-B*35 in Thais
[32]. It is, thus, necessary to investigate whether or not
HLA-B*3505 is also overrepresented in NVP-rash cases in
our study.
Conclusion
We observed higher frequency of HLA-Cw*04  in NVP-
induced skin rash than in NVP-tolerant patients in Thai-
land. In addition to HLA-Cw*04  and/or  HLA-B*3505,
future screening of patients' HLA and genes involved in
hypersensitive reactions may identify other alleles respon-
sible for the incidence of NVP-induced rash. Patients pos-
sessing alleles responsible for NVP-rash should be started
on anti-retroviral therapy without NVP.
Methods
Clinical specimens
A case-control study was carried out with HIV-1 infected
patients who were under treatment at Bamrasnaradura
Infectious Diseases Institute, Ministry of Public Health,AIDS Research and Therapy 2009, 6:22 http://www.aidsrestherapy.com/content/6/1/22
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Nonthaburi, Thailand. The targeted study population
comprised 672 HIV-1/AIDS patients and the study period
ran from March 2007 to March 2008. Patients who devel-
oped apparent skin rash anywhere on the body after NVP
containing HAART and had to change their NVP-contain-
ing regime to efavirenz-containing ones were diagnosed
as rash. There were 39 patients who matched these crite-
ria. Most of these 39 patients developed rash within two
months after NVP treatment (NVP-rash), and none of
them showed liver toxicity. On the other hand, 248
patients showed reasonably good adherence to NVP and
did not develop rash at all or developed only mild rash
that could be controlled by steroid within the observation
period. The remaining 385 patients were excluded
because of treatment without NVP (184 cases), incom-
plete clinical records (101 cases), treatment interruptions
(62 cases), adverse drug effects other than rash (18 cases),
and incomplete HIV-1 suppression (20 cases). From the
248 NVP tolerant patients, we first tried to have two con-
trol patients for each rash case matching age, sex, and
duration of therapy before NVP containing HAART. How-
ever, some rash cases have only one control mainly due to
the limitation of available reagents. Total of 60 samples
were thus selected for the control group (NVP-tolerant).
Age, sex, treatment history and CD4 cell counts were not
different between test and control groups as shown in
Table 1. Two hundred μl of whole blood was collected
from each of those patients and kept at -20°C until DNA
extraction with the QIAamp DNA Blood Mini Kit (QIA-
GEN, Hilden, Germany). All participants signed informed
consent forms. The present study was approved by the
institutional ethics committees of the Bamrasnaradura
Infectious Diseases Institute and the Department of Dis-
eases Control, Ministry of Public Health, Thailand.
HLA-C Typing
Medium-high resolution HLA-C typing was performed
with an HLA-C typing kit (MPH-2 HLA-C typing kit,
Wakunaga, Japan) according to the manufacturer's
instructions. Any ambiguous results were checked by
nucleotide sequence determination of PCR-amplified
DNA fragments of HLA-C exons 2, and 3 [33]. GeneAmp®
PCR system 9600 (Applied Biosystems, Foster City. CA)
was used for all the PCR reactions and DNA sequencer
373 (Applied Biosystems) was used for determination of
the nucleotide sequence of an amplified fragment.
HLA-DRB1*01 detection
We performed HLA class II DNA-based typing of DR1 as
described in the 12th International Histocompatibility
Working Group version 1.5. Amplified DNA with primer
pair 2DRBAMP1 (5'-TTCTTGTGGCAGCTTAAGTT-3') and
2DRBAMP-B(5'-CCGCTGCACTGTGAAGCTCT-3') in
exon 2 was treated with NaOH and the denatured DNA
was loaded onto a nylon membrane manually using a
milliblot system with a vacuum manifold. UV light was
used to crosslink the DNA to the membrane. For hybridi-
zation with DR1 specific probe, we used DRB 1001w (5'-
TGGCAGCTTAAGTTTGAA-3') digoxigenin-labeled SSOP
for detection of HLA-DRB1*01  positive sample. After
stringent wash procedure, the membrane was incubated
with an antibody to digoxigenin coupled with alkaline
phosphatase. Addition of a substrate for alkaline phos-
phatase caused light to be emitted by the Lumiphos. This
light was detected by exposure of X-ray film.
HLA-C 5' SNP genotyping
The rs9264942 SNP genotyping was performed by Taq-
Man SNP genotyping system with ABI real time PCR 7300.
A validated primer and probe mix (C__29901957_10)
were purchased from Applied Biosystems.
Statistical analysis
Differences in age, duration of therapy before start of NVP
containing HAART, and pre- and post-therapy CD4 cell
counts between case and control groups were evaluated by
Mann-Whitney U test. A difference in proportion of sex
was evaluated by Chi square test. Differences in the allele
frequencies between the two groups were evaluated by
Fisher's exact test. P values less than 0.05 were considered
to be statistically significant. The corrected P (Pc) values
were calculated by using Bonferroni's correction.
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